AI基金财通资管数字经济混合发起式A（017483）披露2025年中期报告，上半年基金利润9207.94万元，加权平均基金份额本期利润0.243元。报告期内，基 金净值增长率为29.5%，截至上半年末，基金规模为6.49亿元。 该基金属于偏股混合型基金，长期投资于TMT股票。截至9月2日，单位净值为1.824元。基金经理是包斅文，目前管理的3只基金近一年均为正收益。其中， 截至9月2日，财通资管数字经济混合发起式A近一年复权单位净值增长率最高，达141.68%；财通资管创新成长混合A最低，为87.28%。 基金管理人在中期报告中表示，展望下半年，我们认为宏观经济的增长压力依旧存在，中国经济正处于新旧动能的转换关键期，新质生产力、未来产业依然 是我们投资的重点。总体看在宏观经济压力较大时市场流动性依然会比较宽松。我们认为总体对权益市场较为友好，作为管理人应当积极把握其中结构性的 机会。另外我们也会积极关注经济刺激政策超预期带来的风格切换的行情，也积极做好相应投资预案。 截至9月2日，财通资管数字经济混合发起式A近三个月复权单位净值增长率为50.21%，位于同类可比基金96/328；近半年复权单位净值增长率为43 ...

中国经济网北京9月3日讯今日，中海基金公告，中海医药混合增聘姚炜，梁静静离任。 姚炜历任凯基证券(原台证证券)上海代表处分析师、光大证券国际有限公司分析师、交银国际(上海)股 权投资管理有限公司分析师、兴业证券股份有限公司高级分析师。2017年10月进入中海基金，曾任高级 分析师兼基金经理助理，现任基金经理。 中海医药混合A/C成立于2014年12月17日，截至2025年9月2日，其今年来收益率为33.55%、32.73%，成 立来收益率为142.15%、121.29%，累计净值为2.4740元、2.3100元。 | 基金名称 | 中海医药健康产业精选灵活配置混合型证券投资基金 | | --- | --- | | 基金简称 | 中海医药混合 | | 基金主代码 | 000878 | | 基金管理人名称 | 中海基金管理有限公司 | | 公告依据 | 《公开募集证券投资基金信息披露管理办法》 | | 基金经理变更类型 | 增聘基金经理、解聘基金经理 | | 新任基金经理姓名 | 姚炜 | | 共同管理本基金的其他经 | | | 理姓名 | | | 离任基金经理姓名 | 梁静静 | ...

Group 1 - Zhongke Chuangda's stock increased by 5.1%, reaching 78.17 CNY per share, with a trading volume of 750 million CNY and a turnover rate of 2.65%, resulting in a total market capitalization of 35.959 billion CNY [1] - Zhongke Chuangda, established on March 7, 2008, and listed on December 10, 2015, is a leading global provider of intelligent operating systems and edge intelligent products and technologies [1] - The company's revenue composition includes software development (37.17%), technical services (31.38%), product sales and others (29.20%), and software licensing (2.24%) [1] Group 2 - Huazhong Fund's Huazhong Chuangye 50 ETF (159949) reduced its holdings by 221,400 shares in the second quarter, now holding 3.3233 million shares, which accounts for 0.9% of the circulating shares [2] - The estimated floating profit from this transaction is approximately 12.5954 million CNY [2] - The Huazhong Chuangye 50 ETF was established on June 30, 2016, with a current scale of 25.16 billion CNY and a year-to-date return of 39.29%, ranking 651 out of 4222 in its category [2]

Core Insights - The Honghu Fund, the largest and earliest established insurance private equity fund, has become a major shareholder in at least six listed companies, indicating a strategic investment approach focused on stable, high-dividend blue-chip companies [1][2] Group 1: Fund Overview - The Honghu Fund has established four funds with a total scale of 110 billion yuan, managed by Guofeng Xinghua, a joint venture of Guoshou Asset and Xinhua Asset [1] - The first phase of the Honghu Fund has a scale of 50 billion yuan, with investments fully deployed by March 2023 [2] - The second phase has nearly completed its investment allocation by the end of Q2 2023, while the third phase commenced in early July 2023 [2] Group 2: Investment Characteristics - The investment criteria for the Honghu Fund include companies with good governance, stable operations, relatively stable dividends, good liquidity, and strong returns [1] - The selected companies exhibit characteristics of high dividend yields and large market capitalizations, with companies like Shaanxi Coal and China Shenhua yielding over 5% [1] Group 3: Performance and Impact - The pilot fund's risk indicators are below the benchmark, while its return indicators exceed the benchmark, achieving both functional and profitability success [2] - The pilot fund aims to enhance equity investment and long-term investment capabilities for insurance companies, contributing to market stability and fostering a positive interaction between insurance funds and capital markets [2]

Group 1: Mona Lisa (002918) - The company's revenue from distribution channels decreased by 10% year-on-year in the first half of 2025, while the engineering channel saw a decline of 42.68% [1] - The distribution channel accounted for 82.98% of revenue in Q2, with ongoing declines in engineering [1] - The company is facing intense industry competition with no positive price changes, and is focusing on cost reduction and efficiency improvements [1] - The strategic customer business proportion has dropped to 17%, with 83% of demand coming from non-real estate sectors [1] - The company maintains a "large tiles, large building materials, large home" strategy, with low financial investment proportion [1] Group 2: Mountain Outside Mountain - The domestic market for blood purification equipment generated revenue of 152 million yuan, a year-on-year increase of 14.60% [2] - Blood purification consumables revenue reached 85.34 million yuan, up 46.17%, with self-produced consumables growing by 91.90% [2] - R&D investment increased by 37.12% to 36.51 million yuan, while sales expenses rose by 26.64% to 62.80 million yuan [2] - The overseas market revenue was 86.82 million yuan, reflecting a growth of 41.30%, with significant increases in North America and Africa [2] - The company is a drafting unit for national standards and is enhancing its international competitiveness through core technology [2] Group 3: Leyard (300296) - The smart display segment experienced a 20% quarter-on-quarter growth, driven by high demand in overseas markets, particularly North America [3] - Business growth is supported by demand from cinemas, virtual shooting, and large events [3] - The company is optimizing production capacity across its factories in Slovakia, Shenzhen, and Wuxi to mitigate tariff impacts [3] - The AR glasses are expected to launch in October, targeting B-end customers [3] - The AI and spatial computing segments saw a year-on-year decline due to price reductions and increased R&D investment [3]

Group 1: Dekoli - The company is experiencing rapid growth in computing power demand, but faces challenges with insufficient production capacity and supply chain resources, leading to order delivery issues [1] - Revenue from data communication products is increasing, with access and data products accounting for nearly 40% of total revenue; however, telecom business revenue has decreased by approximately 8% year-on-year [1] - A new factory is expected to be operational in the second half of the year, which is anticipated to improve the situation; OCS products have received orders worth millions [1] - The company's factory in Thailand is projected to start production after the 2026 Spring Festival, with some clients already certified [1] - The company emphasizes enhancing core competitiveness to address uncertainties in tariff policies [1] Group 2: Xinmai Medical - The company reported a revenue of 714 million yuan and a net profit of 315 million yuan during the reporting period, with a proposed cash dividend of 1.3 yuan per share, totaling 157 million yuan [1] - The Cratos product was launched domestically in March, with a listing price below 100,000 yuan, and its promotion is exceeding expectations; Hector has received custom certification in the EU and has completed clinical implants in multiple countries [1] - Research and development investment is expected to be around 10% this year, maintaining a range of 10%-15% in the future [1] - Overseas revenue has increased by over 95% year-on-year, accounting for 17% of total revenue, primarily due to the consolidation of Lombard and organic growth, with plans to expand coverage from 45 to 60 countries next year [1] - High-margin products such as Talos, Cratos, and Fontus are set to be launched internationally [1] Group 3: Green Fund - Green Fund was established in 2016, with total assets under management of 25.643 billion yuan, ranking 110 out of 210 in public funds [2] - The fund has 61 public funds under management, ranking 91 out of 210, and employs 12 fund managers, ranking 97 out of 210 [2] - The best-performing public fund product in the past year is the Green High Dividend Preferred Mixed A, with a latest net value of 1.84 and a growth of 118.24% over the past year [2] - The latest public fund product launched is the Green Technology Growth Mixed A, which is equity-oriented and has a subscription period from August 8, 2025, to November 7, 2025 [2]

Core Insights - The article discusses the recent disclosures of half-year reports from listed companies, highlighting the investments made by the Honghu Fund, which is the largest and earliest established private equity fund backed by insurance capital in China [1][2]. Group 1: Honghu Fund Investments - Honghu Fund has become a top ten shareholder in at least six listed companies, including China Petroleum, China Shenhua, and China Petrochemical [1]. - The investment criteria for Honghu Fund include companies with good governance, stable operations, relatively stable dividends, good liquidity, and strong returns, focusing on large-cap blue-chip companies [1]. - The companies in which Honghu Fund has invested exhibit characteristics of high dividend yields and large market capitalizations, with dividend yields exceeding 5% for companies like Shaanxi Coal and China Shenhua [1]. Group 2: Fund Performance and Strategy - As of the end of the second quarter, the second phase of the Honghu Fund has nearly completed its investment allocation, while the third phase commenced in early July and is progressing smoothly [2]. - The pilot fund has achieved lower risk indicators and higher return indicators compared to benchmarks, indicating a successful balance between functionality and profitability [2]. - The pilot fund's total amount has reached 222 billion yuan, with the first two batches of pilot institutions approved to establish private equity fund companies [2].

Group 1 - The company will adopt the "index return method" for the valuation of "Chip Original Co., Ltd." (stock code: 688521) held by its funds (excluding ETFs) starting from September 2, 2025, based on the AMAC industry index [1] - Valuation will revert to using the closing price on the trading day once "Chip Original Co., Ltd." resumes trading and demonstrates active market trading characteristics, with no further announcements required [1] - The announcement is made in accordance with the guidelines from the China Securities Regulatory Commission and the Asset Management Association of China [1]

Core Viewpoint - The announcement details the fundraising process for the招商均衡优选混合型证券投资基金, which has reached its maximum fundraising limit of RMB 5 billion, leading to a partial confirmation of subscription applications based on a "last day proportion confirmation" principle [1][3][4]. Fundraising Details - The maximum fundraising limit for the fund is set at RMB 5 billion, excluding interest accrued during the fundraising period [3][4]. - The fundraising period began on September 2, 2025, and was originally scheduled to end on September 12, 2025, but was concluded early on September 2, 2025, due to reaching the fundraising cap [7]. - Investors whose applications are not confirmed will have their subscription amounts refunded after the fundraising period ends [4][7]. Investor Information - Investors can check detailed information about the fund on the company's website or contact customer service for inquiries [1][4][7]. - The fund management company emphasizes the importance of reading the fund contract and prospectus to understand the risk-return characteristics of the fund [4].

Fund Overview - The fund is named "Penghua Shanghai Stock Exchange Science and Technology Innovation Board Comprehensive Index Enhanced Securities Investment Fund" with A and C class share codes 024883 and 024884 respectively [8][9] - The fund is a contractual open-end stock fund [2][8] - The initial value of each fund share is set at 1.00 RMB [9] Fundraising Details - The fundraising period is from September 17, 2025, to October 15, 2025 [3][15] - The maximum fundraising scale is capped at 2 billion RMB, excluding interest accrued during the fundraising period [10][26] - The fund is open to individual investors, institutional investors, qualified foreign investors, and other investors permitted by laws and regulations [12][26] Subscription Process - Investors must open an open-end fund account with the fund management company to subscribe [27][29] - The minimum subscription amount for each transaction account is 1 RMB, while the minimum for the direct sales center is 1 million RMB for the first subscription and 10,000 RMB for additional subscriptions [24][4] - Investors can make multiple subscriptions during the fundraising period, but once a subscription application is accepted, it cannot be revoked [5][22] Fee Structure - The A class shares will incur subscription fees, while C class shares will not [17][18] - Subscription fees for A class shares vary based on the type of investor, with specific rates for pension clients [17][18] Fund Management and Custody - The fund is managed by Penghua Fund Management Co., Ltd., and the custodian is Industrial and Commercial Bank of China [1][49] - The fund management company is responsible for managing and operating the fund assets with a commitment to diligence and integrity [6][7] Regulatory Compliance - The fund's registration has been approved by the China Securities Regulatory Commission (CSRC) [1] - The fund contract will become effective once the fundraising conditions are met, including a minimum of 200 investors and a total fundraising amount of at least 200 million RMB [15][45] Investor Rights and Responsibilities - Investors are encouraged to understand the risks and returns associated with the fund before investing [6][7] - The fund management company will return the subscription funds with interest if the fundraising conditions are not met by the end of the period [46]